199 related articles for article (PubMed ID: 20347959)
1. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research.
Lisi A; Botto LD; Robert-Gnansia E; Castilla EE; Bakker MK; Bianca S; Cocchi G; de Vigan C; Dutra Mda G; Horacek J; Merlob P; Pierini A; Scarano G; Sipek A; Yamanaka M; Mastroiacovo P
Reprod Toxicol; 2010 Jul; 29(4):433-42. PubMed ID: 20347959
[TBL] [Abstract][Full Text] [Related]
2. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE).
Arpino C; Brescianini S; Robert E; Castilla EE; Cocchi G; Cornel MC; de Vigan C; Lancaster PA; Merlob P; Sumiyoshi Y; Zampino G; Renzi C; Rosano A; Mastroiacovo P
Epilepsia; 2000 Nov; 41(11):1436-43. PubMed ID: 11077457
[TBL] [Abstract][Full Text] [Related]
3. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study.
Meijer WM; Cornel MC; Dolk H; de Walle HE; Armstrong NC; de Jong-van den Berg LT;
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):675-82. PubMed ID: 16761260
[TBL] [Abstract][Full Text] [Related]
4. Fostering international collaboration in birth defects research and prevention: a perspective from the International Clearinghouse for Birth Defects Surveillance and Research.
Botto LD; Robert-Gnansia E; Siffel C; Harris J; Borman B; Mastroiacovo P
Am J Public Health; 2006 May; 96(5):774-80. PubMed ID: 16571708
[TBL] [Abstract][Full Text] [Related]
5. Acardia: epidemiologic findings and literature review from the International Clearinghouse for Birth Defects Surveillance and Research.
Botto LD; Feldkamp ML; Amar E; Carey JC; Castilla EE; Clementi M; Cocchi G; de Walle HE; Halliday J; Leoncini E; Li Z; Lowry RB; Marengo LK; Martínez-Frías ML; Merlob P; Morgan M; Muñoz LL; Rissmann A; Ritvanen A; Scarano G; Mastroiacovo P
Am J Med Genet C Semin Med Genet; 2011 Nov; 157C(4):262-73. PubMed ID: 22002952
[TBL] [Abstract][Full Text] [Related]
6. Cloacal exstrophy: an epidemiologic study from the International Clearinghouse for Birth Defects Surveillance and Research.
Feldkamp ML; Botto LD; Amar E; Bakker MK; Bermejo-Sánchez E; Bianca S; Canfield MA; Castilla EE; Clementi M; Csaky-Szunyogh M; Leoncini E; Li Z; Lowry RB; Mastroiacovo P; Merlob P; Morgan M; Mutchinick OM; Rissmann A; Ritvanen A; Siffel C; Carey JC
Am J Med Genet C Semin Med Genet; 2011 Nov; 157C(4):333-43. PubMed ID: 22002951
[TBL] [Abstract][Full Text] [Related]
7. [In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].
Bonnot O; Vollset SE; Godet PF; d'Amato T; Dalery J; Robert E
Encephale; 2003; 29(6):553-9. PubMed ID: 15029090
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring of pregnancies exposed to drugs in France: the experience of the registries of congenital malformations].
Doray B
Therapie; 2014; 69(1):47-51. PubMed ID: 24698188
[TBL] [Abstract][Full Text] [Related]
9. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations.
Queisser-Luft A; Eggers I; Stolz G; Kieninger-Baum D; Schlaefer K
Am J Med Genet; 1996 May; 63(1):268-76. PubMed ID: 8723120
[TBL] [Abstract][Full Text] [Related]
10. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens.
Colvin L; Slack-Smith L; Stanley FJ; Bower C
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1137-50. PubMed ID: 20602344
[TBL] [Abstract][Full Text] [Related]
11. Using the Hungarian Birth Defects Registry for surveillance, research and intervention.
Siffel C; Czeizel AE
Cent Eur J Public Health; 1997 Jun; 5(2):79-81. PubMed ID: 9208163
[TBL] [Abstract][Full Text] [Related]
12. Using active birth defects surveillance programs to supplement data on fetal death reports: improving surveillance data on stillbirths.
Duke W; Williams L; Correa A
Birth Defects Res A Clin Mol Teratol; 2008 Nov; 82(11):799-804. PubMed ID: 18985684
[TBL] [Abstract][Full Text] [Related]
13. Maternal asthma, asthma medication use, and the risk of congenital heart defects.
Lin S; Herdt-Losavio M; Gensburg L; Marshall E; Druschel C
Birth Defects Res A Clin Mol Teratol; 2009 Feb; 85(2):161-8. PubMed ID: 19067406
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing surveillance for human teratogenicity: a model approach.
Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
[TBL] [Abstract][Full Text] [Related]
15. Surveillance study of Sinupret in comparison with data of the Mainz birth registry.
Ismail C; Wiesel A; März RW; Queisser-Luft A
Arch Gynecol Obstet; 2003 Feb; 267(4):196-201. PubMed ID: 12592417
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.
Crider KS; Cleves MA; Reefhuis J; Berry RJ; Hobbs CA; Hu DJ
Arch Pediatr Adolesc Med; 2009 Nov; 163(11):978-85. PubMed ID: 19884587
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of teratogenic risk: the contribution of abnormalities registries].
De Wals P
Rev Epidemiol Sante Publique; 1994; 42(5):392-8. PubMed ID: 7972998
[TBL] [Abstract][Full Text] [Related]
18. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980-1996.
Czeizel AE; Rockenbauer M; Siffel C; Varga E
Teratology; 2001 May; 63(5):176-85. PubMed ID: 11320528
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of selected characteristics of pregnancy drug registries.
Honein MA; Paulozzi LJ; Cragan JD; Correa A
Teratology; 1999 Dec; 60(6):356-64. PubMed ID: 10590397
[TBL] [Abstract][Full Text] [Related]
20. Population and case-control surveillance in the search for environmental causes of birth defects.
Oakley GP
Public Health Rep; 1984; 99(5):465-8. PubMed ID: 6207556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
